Deerfield Management Company, L.P. (Series C) Xeris Biopharma Holdings, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 22,574 shares of XERS stock, worth $208,583. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,574Holding current value
$208,583% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding XERS
# of Institutions
212Shares Held
90MCall Options Held
81.6KPut Options Held
57.6K-
Black Rock Inc. New York, NY10.3MShares$95.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$90.7 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.84MShares$35.4 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$35 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.65MShares$33.7 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $1.26B
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...